Kiniksa Pharmaceuticals International, plc Logo

Kiniksa Pharmaceuticals International, plc

Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.

KNSA | US

Overview

Corporate Details

ISIN(s):
BMG5269C1010
LEI:
Country:
United States of America
Address:
23 OLD BOND STREET, FLOOR 3, LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for debilitating diseases with significant unmet medical needs. The company's portfolio is centered on innovative, immune-modulating assets. Its pipeline includes investigational therapies for conditions such as recurrent pericarditis, addressing diverse patient needs through novel treatments. Kiniksa operates with a patient-centric mission, aiming to deliver therapies to individuals with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kiniksa Pharmaceuticals International, plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kiniksa Pharmaceuticals International, plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kiniksa Pharmaceuticals International, plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.